Results 131 to 140 of about 47,525 (299)

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT A physiologically based pharmacokinetic (PBPK) model was developed and verified for dordaviprone, a small molecule with antitumor effects in glioma patients. The model was applied to assess the drug–drug interaction (DDI) potential of dordaviprone as a victim of CYP3A4 inhibitors and inducers, and as a perpetrator of CYP3A4, CYP2C8, CYP2D6 ...
Jaiswal S, Patel NK, Jones HM, McFeely S, Faison SL, Tippin T, Naderer O.   +6 more
europepmc   +2 more sources

In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine [PDF]

, 1996
Zhenhua Xu, Hong‐Guang Xie, Hong‐Hao Zhou   +2 more
openalex   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2 [PDF]

, 1997
S. Ball, Dennis Ahern, JoAnn Scatina, John Y. Kao   +3 more
openalex   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Duloksetins betydning for serumkonsentrasjonen av psykofarmaka som omsettes via CYP2D6 [PDF]

, 2009
Bakgrunn: Duloksetin er et relativt nytt antidepressivum som hemmer reopptak av serotonin og noradrenalin intersynaptisk. Det metaboliseres via Cytokrom P450 2D6 (CYP2D6) og CYP1A2, men antas også å være en svak/moderat hemmer av CYP2D6.
Enoksen, Torill Bakko
core  

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication [PDF]

, 1998
Linda S. W. Steijns, Jan van der Weide
openalex   +1 more source

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R. Raber, Maria Lavinea Novis de Figueiredo, Manthena V. S. Varma   +6 more
wiley   +1 more source

Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. [PDF]

, 1996
C Beyeler, Melissa J. Armstrong, H. A. Bird, Jeffrey R. Idle, Ann K. Daly   +4 more
openalex   +1 more source

Six New Cases of 22q13.2 Gain Including TFC20: First Report of Triplication and Smallest Duplication Associated With Neurodevelopmental Delays

Clinical Genetics, EarlyView.
This study reports six new cases of 22q13.2 duplication and triplication, including the TCF20 gene, associated with neurodevelopmental disorders and various morphological and systemic abnormalities. The findings suggest a variable expressivity, but their complete penetrance remains uncertain compared to well‐established loss‐of‐function variants ...
Etienne Bizot, Dima Jouni, Caroline Rooryck, Juliet Taylor, Marine Legendre, Lorelei Charbonnier, Julia Metreau, Emmanuelle Benaloun, Audrey Pinson, Geneviève Quenum, Jérôme Bouligand, Gérard Tachdjian, Philippe Labrune, Lucie Tosca   +13 more
wiley   +1 more source